Navigation Links
NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Date:3/24/2008

IRVINE, Calif., March 24 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals, Inc. (OTC Bulletin Board: NURX) today announced it has dosed the first patient in a Phase I clinical trial of the first-in-class rexinoid receptor (RXR) agonist NRX4204.

The single-center study, which NuRx expects to complete in the fourth quarter of this year, is designed to evaluate the safety and tolerability of the compound. NRX4204 is the company's first drug candidate in clinical trials.

"Our preclinical data show that NRX4204 is a highly potent and specific, orally bio-available RXR agonist that is effective in models of non-small cell lung cancer and breast cancer," said Harin Padma-Nathan, M.D., NuRx's president and CEO. "We intend to pursue the development of this compound as a treatment for both indications. There are no rexinoid treatments currently approved for these indications."

NuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation retinoid and rexinoid compounds for application in oncology (treatment, prevention and adjunctive supportive therapy) and other highly prevalent diseases. The company's lead compounds are NRX4204, a highly specific, first-in-class rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer and a RAR agonist for the treatment of acute leukemia. Based in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. Th
'/>"/>

SOURCE NuRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Germany , August 28, 2014 ... available free of charge for people from 40 to 65 ... next two decades. Using a traffic light color scheme, the ... at risk. The new "CAIDE Dementia Risk App ... developed in collaboration with Karolinska Institutet in Stockholm ...
(Date:8/28/2014)... , Aug. 28, 2014 Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today ... of cGMP manufacturing of SYN-004, Synthetic Biologics, proprietary ... Clostridium difficile ( C. difficile ) infections. ...
(Date:8/28/2014)... -- Today is the official launch of a newly ... and pharmaceutical organizations that will work together to help ... medication. The Coalition will initially focus its efforts on ... nonmedical use vary, a 2013 study at one large ... college students reported nonmedical use of prescription stimulant medication ...
Breaking Medicine Technology:CAIDE Looks into the Future: New App from Merz Pharmaceuticals Assesses the Risk of Getting Dementia Within the Next 20 Years 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 4Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 5New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 2New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 3New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 4New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 5New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 6
... Inc. (Nasdaq: CRDC ) today announced that ... Proximal Anastomosis System during on- and off-pump coronary artery ... secure connection, or anastomosis, between a vein graft and ... during CABG procedures and was first shipped to Japan ...
... PHILADELPHIA, Jan. 26, 2012  The IP & Science ... Brazil,s Institute for Applied Economic Research (IPEA). This ... Policies for Innovation, Regulation and Infrastructure (DISET) branch ... of products, including generic pharmaceutical intelligence and tools ...
Cached Medicine Technology:Cardica Achieves Key Milestone With Over 25,000 PAS-Port® Proximal Anastomosis Systems Deployed Worldwide 2Thomson Reuters Helps Brazil's Institute for Applied Economic Research Identify New Generic Drug Opportunities 2
(Date:8/28/2014)... 2014 Canadian Linen and Uniform Service, ... America, today announced the launch of its new Customer ... with Canadian Linen even easier and more convenient for ... account information online and better communicate with the company. ... ability to:, , Access, download and ...
(Date:8/28/2014)... After more than two years of designing ... to announce the opening of Houston’s Mirror Mirror Beauty ... Mirror Mirror Beauty Boutique offers premium aesthetic services in ... of Richmond and Drexel near Highland Village, Mirror Mirror ... technology in a private, easy to access location. Patients ...
(Date:8/28/2014)... 28, 2014 Clarity PSO , ... re-certified as a federal Patient Safety Organization (PSO) for ... for Healthcare Research and Quality (AHRQ). Clarity PSO will ... and services following the true intentions of the Patient ... ”We are proud and eager to continue our journey ...
(Date:8/28/2014)... 2014 CMMI (Center for Medicare and Medicaid ... care to address patient needs. What does it all mean? ... (with more provider accountability) and reduce the cost of care. ... in the care of a patient get a single payment ... distribute it. If it sounds complicated, that's because it is. ...
(Date:8/28/2014)... 28, 2014 On September 10, the ... Isaacs, the chairperson, president and CEO of Aduro BioTech, ... the Mesothelioma Experts live broadcast. The interview will ... mesothelioma expert nurse practitioner, Mary Hesdorffer, APRN . ... Aduro BioTech’s experimental therapy for malignant pleural mesothelioma, known ...
Breaking Medicine News(10 mins):Health News:Canadian Linen and Uniform Service Launches New Customer Portal 2Health News:Canadian Linen and Uniform Service Launches New Customer Portal 3Health News:Mirror Mirror Beauty Boutique to Welcome Its First Patients 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3Health News:Med-Certification.com Expects Industry "Hiccups" with New Models for Patient Care and Reimbursement 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 3
... 6 Align Technology, Inc. (Nasdaq: ALGN ) ... speak at two upcoming financial conferences. Both presentations, as noted ... section of Align Technology,s website at http://investor.aligntech.com . An ... three months. , Conference: Bank ...
... M. D. Anderson Clinical Services Outside of Houston PHOENIX, ... University of Texas M. D. Anderson Cancer Center announced ... here. The initiative joins Arizona,s leading provider of health care ... their families with an unprecedented level of cancer care in ...
... Africa, May 6 The healthcare industry ... vast inequalities in access to care. The ... 85.0% of the population, yet accounts for ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )Public-private partnerships offer an innovative ...
... and wife Ellen honored for generous contribution to New York University ... ... -- Dr. Jan Linhart, D.D.S. and his wife, Ellen Linhart, have ... Education Program at Dr. Linhart’s alma mater. In honor of this ...
... largest hospital ship charity were honored with a humanitarian award at a ... ... May 6, 2009 -- The founders of the world,s largest hospital ship ... London last night. , , , , ,The annual Variety ...
... innovation is L-Tox, for advanced liver support. L-Tox was formulated to ... , ... Anaheim, California (PRWEB) May 6, 2009 - ... a stop product use directive on May 1, 2009. All consumers ...
Cached Medicine News:Health News:Align Technology Executives to Present at Upcoming Financial Conferences 2Health News:Banner Health, M. D. Anderson Announce Cancer Care Facility for Arizona 2Health News:Banner Health, M. D. Anderson Announce Cancer Care Facility for Arizona 3Health News:South Africa not Gaining the Full Benefit of PPPs in the Healthcare Sector, Says Frost & Sullivan 2Health News:South Africa not Gaining the Full Benefit of PPPs in the Healthcare Sector, Says Frost & Sullivan 3Health News:Manhattan Dentist Inducted Into The Sir Harold Acton Society 2Health News:Mercy Ships Founders Receive Humanitarian of the Year Award From Variety Club 2Health News:Mercy Ships Founders Receive Humanitarian of the Year Award From Variety Club 3Health News:Mercy Ships Founders Receive Humanitarian of the Year Award From Variety Club 4Health News:Max Muscle Sports Nutrition Offers Support for Hydroxycut Recall 2Health News:Max Muscle Sports Nutrition Offers Support for Hydroxycut Recall 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: